Alberts Leonie, El Sharouni Sherif Y, Hofman Frederik N, Van Putte Bart P, Tromp Ellen, Van Vulpen Marco, Kastelijn Elisabeth A, Schramel Franz M N H
Department of Pulmonology, St. Antonius Hospital, Nieuwegein, the Netherlands.
Department of Radiotherapy, University Medical Center, Utrecht, the Netherlands.
Anticancer Res. 2015 Dec;35(12):6773-9.
To evaluate changes in pulmonary function tests (PFTs) at different follow-up durations after stereotactic body radiotherapy (SBRT) and surgery in stage I and II non-small-cell lung cancer (NSCLC).
Differences between pre-treatment- and follow-up PFTs were analyzed in 93 patients treated with surgery and 30 patients treated with SBRT for NSCLC. Follow-up durations were categorized into: early (0-9 months), middle (10-21 months) and late (≥22 months). Wilcoxon signed-rank test was used to analyze differences between pre-treatment and follow-up PFTs.
Forced expiratory volume in one second, forced vital capacity and diffusion capacity for carbon monoxide corrected for the actual hemoglobin level significantly diminished after surgery for all follow-up durations: 11-17% of predicted values. After SBRT, PFTs remained stable, but a declining trend of 6% (p=0.1) was observed after 22 months.
SBRT might lead to less treatment-related toxicity measured by PFTs than surgery in both the short and long term.
评估立体定向体部放疗（SBRT）和手术治疗Ⅰ期和Ⅱ期非小细胞肺癌（NSCLC）后不同随访时间的肺功能测试（PFT）变化。
分析93例接受手术治疗的NSCLC患者和30例接受SBRT治疗的NSCLC患者治疗前和随访时PFT的差异。随访时间分为：早期（0 - 9个月）、中期（10 - 21个月）和晚期（≥22个月）。采用Wilcoxon符号秩检验分析治疗前和随访时PFT的差异。
术后所有随访时间的一秒用力呼气容积、用力肺活量和根据实际血红蛋白水平校正的一氧化碳弥散量均显著下降：降至预测值的11 - 17%。SBRT后，PFT保持稳定，但22个月后观察到有6%的下降趋势（p = 0.1）。
短期和长期来看，通过PFT测量，SBRT导致的治疗相关毒性可能比手术少。
